ClinicalTrials.gg
CompletedNCT00137007Updated Apr 22, 2011

Zithromax EV in Community-Acquired Pneumonia (CAP)

A Phase 4 interventional study of Azithromycin and Ampicillin/sulbactam in Pneumonia, sponsored by Pfizer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-22.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing azithromycin in Pneumonia — 1 open to participants now, 2 under way, 1 of them phase 3. Azithromycin · Pneumonia.

Enrollment
7th of 13
151 · median 151
Started
2003
with 3 others
Phase 4
6 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
3 of 13
Pfizer

Among the 13 studies testing azithromycin in Pneumonia, this one is the 7th largest by enrollment, is one of 4 that started in 2003, is one of 6 in phase 4, and was the 2nd registered.

Pneumonia

1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

1 of the 13 studies testing azithromycin in Pneumonia is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About azithromycin

Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing azithromycin in Pneumonia, or all of them as a file.
02

Study summary

The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide.

This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy.

03

Conditions studied

  • Pneumonia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must require hospitalization and intravenous therapy.
  • Subjects must have a Fine pneumonia score > 70 (Fine Class > II).
  • Subjects must have a medical history and clinical and radiological findings consistent with a community-acquired bronchopneumonia or lobar pneumonia. The following criteria must be met:

    • new infiltrate(s) on chest X-ray; AND
    • at least two of the CAP signs or symptoms.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the baseline visit, or treatment for more than 7 days within 15 days.
  • Specific systemic diseases or other medical conditions that would interfere with the evaluation of the therapeutic response or safety of the study drug, including:

    • Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis carinii pneumonia;
    • Neutropenia;
    • Cavitary lung disease by chest X-ray;
    • Primary lung cancer or other to the lung;
    • Aspiration pneumonia;
    • Empyema;
    • Known or suspected tuberculosis;
    • Neoplastic disease;
    • Cystic fibrosis;
    • A history of any form of epilepsy or seizure;
    • DDM;
    • Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia (this does not exclude patients with );
    • Significant gastrointestinal or other conditions which may affect study drug absorption; and
    • Significant cardiovascular disorders.
  • therapy, defined as chronic treatment with known immunosuppressant medications
  • Impaired hepatic function, as shown by, but not limited to, , (SGOT), or ALT (SGPT) greater than three times the laboratory , or total greater than two times the upper limit of normal.
  • Subjects already hospitalized or who resided in a long-term-care facility for greater than 14 days before the onset of symptoms.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the clinical efficacy of intravenous (IV) azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams twice a day (BID) for 2 to 5 days

  2. followed by oral azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams.

Secondary outcomes

  1. To evaluate the eradication of baseline pathogens of IV azithromycin plus IV ampicillin/sulbactam followed by oral azithromycin plus IV ampicillin/sulbactam at Visit 3 and Visit 4

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 29, 2005
Start
Nov 2003
CompletionActual
Sep 2005
Last update
Apr 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00137007
Lead sponsor
Pfizer
First posted
Aug 29, 2005
Start date
Nov 2003
Completion
Sep 2005
Last update
Apr 22, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azithromycin · Ampicillin · Sulbactam

Start the discussion